Contemporary Approaches to Relapsed/Refractory Multiple Myeloma: A Focus on BCMA-Targeted Therapeutics
Physicians: maximum of 3.0 AMA PRA Category 1 Credits™
Registered Nurses: 3.0 Nursing contact hours
Released: October 1, 2021 Expiration: October 10, 2022
Provided by Clinical Care Options, LLC
Supported by educational grants from:
Upon completion of this activity, participants should be able to:
• Understand the clinical rationale for incorporating BCMA-targeted agents into the treatment plan for patients with multiple myeloma
• Evaluate the available efficacy, safety, and tolerability data for BCMA-targeted therapies in patients with multiple myeloma
• Identify patients with multiple myeloma who are likely to benefit from treatment with currently available BCMA-targeted therapy
• Select patients with relapsed/refractory multiple myeloma who would be candidates for enrollment on clinical trials of therapies targeting BCMA
• Monitor and mitigate potential adverse events from anti-BCMA therapy in patients with multiple myeloma
Information on this Educational Activity
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Nina Shah, MD, has disclosed that she has received funds for research from Bluebird Bio, Celgene/Bristol-Myers Squibb, Janssen, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and TeneoBio and consulting fees from Amgen, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, and Sanofi
Peter Voorhees, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb and Secura Bio and has served on the Advisory Board for AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, Pfizer, and Sanofi.
Terrence Fagan has no relevant conflicts of interest to report.
Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley has no relevant conflicts of interest to report.
Shara Pantry, PhD, has no relevant conflicts of interest to report.
June Wasserstrom has no relevant conflicts of interest to report.
Jim Mortimer has no relevant conflicts of interest to report.
Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for oncologists, nurses, and other healthcare professionals involved in the management of patients with relapsed/refractory MM.
The goal of this activity is, through the establishment of meaningful small group interactions among clinicians and a variety of collaborative educational experiences, to improve the performance of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with relapsed/refractory multiple myeloma.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this other activity, Gather-ed, for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours.
This program has been made available online.
Instructions for Credit
Participation in this self-study activity should be completed in approximately 3.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 1, 2021, through October 10, 2022.
To claim the maximum amount of credit available, you must complete all of the following: